To our knowledge, no commercially available anti-mGlu3 antibodies have previously been characterised using either approach; the one exception in schizophrenia is provided by Corti et al. (2007) but their anti-mGlu3 antibody was generated in-house and not available to others. The gene discussed is GRM3; the disease is schizophrenia.